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Abstract 
Allergic rhinitis (AR) is impacted by allergens and air pollution but interactions between air pollution, sleep and 
allergic diseases are insufficiently understood. POLLAR (Impact of air POLLution on sleep, Asthma and Rhinitis) is a 
project of the European Institute of Innovation and Technology (EIT Health). It will use a freely‑existing application for 
AR monitoring that has been tested in 23 countries (the Allergy Diary, iOS and Android, 17,000 users, TLR8). The Allergy 
Diary will be combined with a new tool allowing queries on allergen, pollen (TLR2), sleep quality and disorders (TRL2) 
as well as existing longitudinal and geolocalized pollution data. Machine learning will be used to assess the relation‑
ship between air pollution, sleep and AR comparing polluted and non‑polluted areas in 6 EU countries. Data gener‑
ated in 2018 will be confirmed in 2019 and extended by the individual prospective assessment of pollution (portable 
sensor, TLR7) in AR. Sleep apnea patients will be used as a demonstrator of sleep disorder that can be modulated in 
terms of symptoms and severity by air pollution and AR. The geographic information system GIS will map the results. 
Consequences on quality of life (EQ‑5D), asthma, school, work and sleep will be monitored and disseminated towards 
the population. The impacts of POLLAR will be (1) to propose novel care pathways integrating pollution, sleep and 
patients’ literacy, (2) to study sleep consequences of pollution and its impact on frequent chronic diseases, (3) to 
improve work productivity, (4) to propose the basis for a sentinel network at the EU level for pollution and allergy, (5) 
to assess the societal implications of the interaction. MASK paper N°32.
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Background
Exposure to ambient air pollution increases morbidity 
and mortality. It is a leading contributor to global disease 
burden [1, 2]. The role of air pollution on cardiovascular 
events [3], COPD [4], sleep apnea [5] and asthma exacer-
bations [6] is clear. In allergic rhinitis (AR), air pollution 
is one of the risk factors that induces allergic sensitization 
and deteriorates the AR condition, but data are some-
times conflicting [7]. Moreover, data on the impact of air 
pollution on AR multimorbidity [8] or severity are scarce 
[9] and not always conclusive, probably due to methodo-
logical problems.
Meteorological factors such as temperature, sunlight 
and humidity as well as air pollution can affect pollen 
emission and allergenic concentration [10–12]. Traffic-
related pollutants [13] and diesel exhaust particles can 
disrupt pollen, leading to the release of pauci-micro-
nic particles which can penetrate in the bronchi [14]. 
Asthma due to pollen may be associated to peaks of air 
pollution [15–19]. These data suggest an important inter-
action between pollens and pollution, inducing asthma 
in AR patients during the pollen season. However, more 
data should be collected and mobile technology may be 
interesting.
MASK-rhinitis (Mobile Airways Sentinel NetworK for 
allergic rhinitis) is a patient centred ICT system [20]. A 
mobile phone app (Allergy Diary) central to MASK has 
been launched in 23 countries and has been validated 
[21–24].
Many different methods are used to monitor pollen 
exposure [25–28]. Pollen counts can assess the exposure 
of pollen-allergic patients [29]. The assessment of aller-
gen content in the air is feasible [30] but requires sophis-
ticated methods that may not account for all of the pollen 
species in the ambient air. Meteorological data may, in 
the future, be of interest for predicting the onset of the 
season, but more data are required [31]. Combining sev-
eral sources using advanced data engineering may also be 
important but these data are still complex and, in many 
different areas, not yet available for all pollen species 
[25–28, 32]. Google Trends (GT) is a Web-based sur-
veillance tool that uses Google to explore the searching 
trends of specific queries. Recent studies have suggested 
the utility of GT for assessing the seasonality of allergic 
diseases [33–37]. GT reflects the real-world AR epidemi-
ology and could potentially be used as a monitoring tool 
for allergic rhinitis [38, 39].
Interactions between air pollution, sleep quality, sleep 
disorders [40] and allergic diseases are clear but insuf-
ficiently understood. POLLAR (Impact of Air POLLu-
tion on sleep, Asthma and Rhinitis) is a new project of 
the EIT Health that will embed environmental data into 
the Allergy Diary. POLLAR aims at combining emerging 
technologies (search engine Technology Readiness level 
TLR2; sleep assessment, pollution sampler TLR6, Allergy 
Diary TLR9) with machine learning to (1) understand the 
effects of air pollution in allergic rhinitis and its impact 
on sleep, work and asthma, (2) assess societal conse-
quences, shared with citizens, corporate citizens and 
professionals (3) propose preventive strategies and (4) 
develop participative policies.
EIT health
European Institute of Innovation and Technology (EIT) 
and Knowledge and Innovation Communities (KICs)
The European Institute of Innovation and Technology 
(EIT), the research and technological agency of the EU, 
was set up in 2008. It aims to spur innovation and entre-
preneurship across Europe in order to overcome some of 
its greatest challenges. The EIT strengthens cooperation 
among its partners to form dynamic pan-European part-
nerships and to develop favorable environments for crea-
tive thought processes and innovations. Real sustainable 
products, services, entrepreneurs, engineers, scientists, 
companies, revenue, profit and jobs are emerging from 
the Innovation Communities making this innovation net-
work the largest in Europe, if not in the world.
The Knowledge and Innovation Communities (KICs) 
represent a unique feature of the EIT for the integra-
tion of education, research and innovation (the so-called 
Knowledge Triangle) in a common organization. The 
KICs carry out activities that cover the entire innovation 
chain: training and education programmes, reinforcing 
the journey from research to the market, innovation pro-
jects, as well as business incubators and accelerators.
There are currently six Innovation Communities and 
each one focuses on a different societal challenge (https 
://eit.europ a.eu/activ ities /innov ation -commu nitie s): EIT 
Climate-KIC (climate change mitigation and adaptation), 
EIT Digital (Information and Communication Technolo-
gies), EIT InnoEnergy (sustainable energy), EIT Health 
(healthy living and active ageing), EIT Raw Materials 
(sustainable exploration, extraction, processing, recy-
cling and substitution) and EIT Food (putting Europe at 
the centre of a global revolution in food innovation and 
production).
EIT health
EIT Health (European Institute of Innovation and Tech-
nology-Health) is a consortium of over 50 core part-
ners and 90 associate partners from leading businesses, 
research centres and universities across 14 EU countries. 
EIT Health works to give EU citizens greater opportuni-
ties to enjoy a healthier and active life for longer, and to 
postpone dependency on others, by leveraging big data 
and new technologies, identifying and removing barriers 
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to innovation, and building on education and talent crea-
tion (https ://www.eithe alth.eu). EIT Health allows:
  • Innovative products and services to be developed 
in every area imaginable, including climate change, 
healthy living and active and healthy ageing (AHA).
  • New companies to be started.
  • A new generation of entrepreneurs to be trained.
The EIT’s role is to guide the process and set the strate-
gies, but the KICs should put these into practice and pro-
vide results.
Three pillars have been defined:
  • Promote healthy living, self-management of health 
and life style interventions.
  • Support active ageing.
  • Improve healthcare with innovations and a patient-
centric approach, in particular for chronic diseases.
EIT Health brings together the three sides of the 
knowledge triangle through three programmes:
  • Campus (education) provides up-to-date knowledge, 
skills and attitudes to help turn the brightest learners 
into healthcare leaders and entrepreneurs to shape 
the future of Europe’s health. Campus educational 
offerings are intended to increase industry knowl-
edge and deliver novel skills, as EIT seeks to inject an 
entrepreneurial approach into European healthcare 
education (https ://www.eithe alth.eu/campu s).
  • Accelerator (business creation) supports the best and 
brightest health industry entrepreneurs, creating a 
favorable environment for innovation and providing 
skills and services to get promising business ideas 
into the market.
  • Innovation Projects provide comprehensive sup-
port for innovations that show the potential to have 
a positive impact on healthcare for a societal chal-
lenge. The most promising ideas are developed into 
commercially-viable products through a multi-disci-
plinary approach.
The Allergy Diary
MASK (Mobile Airways Sentinel NetworK)
In 2012, the European Commission launched the Euro-
pean Innovation Partnership on Active and Healthy Age-
ing (DG Santé and DG CONNECT) [41]. The B3 Action 
Plan devoted to innovative integrated care models for 
chronic diseases has selected Integrated care pathways 
for airway diseases (AIRWAYS ICPs) [42, 43] with a life 
cycle approach [44] as the model for chronic diseases. 
The Action Plan of AIRWAYS ICPs has been devised 
[42], implemented [45] and scaled up [46, 47]. AIRWAYS 
ICPs is a GARD (WHO Global Alliance for Chronic Res-
piratory Diseases) [48] research demonstration project 
(Fig. 1).
MASK (Mobile Airways Sentinel NetworK) represents 
Phase 3 of ARIA and is an AIRWAYS ICPs tool [20, 49]. 
It represents a Good Practice focusing on the implemen-
tation of multi-sectoral care pathways using emerging 
technologies with real life data in rhinitis and asthma 
multi-morbidity. MASK follows the JA-CHRODIS (Joint 
Action on Chronic Diseases and Promoting Healthy Age-
ing across the Life Cycle, 2nd EU Health Programme 
2008-2013 [50]) recommendations for good practices 
[51].
MASK was initiated to reduce the global burden of rhi-
nitis and asthma, by giving the patient a simple tool to 
better prevent and manage respiratory allergic diseases. 
More specifically, MASK should help to (i) understand 
the disease mechanisms and the effects of air pollution in 
allergic diseases, (ii) better appraise the burden incurred 
by medical needs but also the indirect costs, (iii) propose 
novel multidisciplinary care pathways integrating pollu-
tion and patients’ literacy, (iv) improve work productiv-
ity, (v) propose the basis for a sentinel network at the EU 
level for pollution and allergy and (vi) assess the societal 
implications of the project to reduce health and social 
inequalities globally.
The Allergy Diary
The mobile technology of MASK is the Allergy Diary, an 
App (Android and iOS) which is freely available for AR 
and asthma sufferers in 23 countries (16 EU countries, 
Argentina, Australia, Brazil, Canada, Mexico, Switzer-
land and Turkey) and 17 languages (translated and back-
translated, culturally adapted and legally compliant) [20]. 
Users fill in a simple questionnaire on asthma and rhinitis 
upon registration and daily assess the impact of their dis-
ease using a visual analogue scale (VAS) [52] for global 
allergy symptoms, rhinitis, conjunctivitis, asthma and for 
work. Moreover, two specific questionnaires are applied 
every week to assess disease impact on patients’ QoL 
(EQ-5D) [24] and productivity at work (WPAI-AS) [53]. 
The Allergy Diary is associated with an inter-operable 
tablet with a CDSS for physicians and other health care 
professionals [54].
Pilot studies in up to 17,000 users and over 95,000 days 
are available. The Allergy Diary has been validated [23] 
and has shown that (1) totally anonymized geoloca-
tion can be used in 22 countries (in preparation), (2) the 
Allergy Diary data can be analyzed in 22 countries and 16 
languages, (3) sleep, work productivity and daily activi-
ties are impaired in AR [22, 24], (4) daily work productiv-
ity is associated with AR severity [21], (5) everyday use of 
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medications can be monitored proposing a novel assesse-
ment of treatment patterns (in press), (6) novel patterns 
of multimorbidity have been identified [55] and con-
firmed in epidemiological studies [56, 57] and (7) over 
80% of AR patients self-medicate and are non-observant 
(Menditto, in preparation).
The Allergy Diary (TLR 9, Technology Readiness level) 
represents a validated mHealth tool for the management 
of AR. Asthma has also been monitored but data have 
not yet been analysed. Economic impact can be moni-
tored using work productivity. The results of the Allergy 
Diary have made innovative approaches of AR possible 
and are directly strengthening the Change Management 
(CM) strategies in ARIA.
Transfer of innovation of MASK
A Transfer of Innovation (Twinning) project has been 
funded by the European Innovation Partnership on 
Active and Healthy Ageing using MASK in 22 Refer-
ence Sites or regions across Europe, Australia, Brazil and 
Mexico [58]. This will improve the understanding, assess-
ment of burden, diagnosis and management of rhinitis in 
old age by comparison with an adult population. Specific 
objectives are: (1) to assess the percentage of adults and 
elderly who are able to use the Allergy Diary, (2) to study 
phenotypic characteristics and treatment over a period of 
one year of rhinitis and asthma multimorbidity at base-
line (cross-sectional study) (3) to provide some insight 
into the differences between elderly people and adults in 
terms of response to treatment and practice.
The Twinning has been tested in Germany (Region 
Kohl-Bohn) in a pilot study that has now been extended 
to the other countries of the Twinning project.
Pollar
Goals
AR and asthma impact the social life, school and work 
[59] of dozens of millions of EU citizens [21]. Their 
impact on work productivity is estimated to cost 30–50 
billion € per year in the EU. AR affects sleep quality and 
the severity of sleep disorders, namely sleep apnea, and 
is associated with asthma. AR and asthma induce health 
and social inequalities across the life cycle. Air pollution 
has a significant impact on AR severity and its conse-
quences. The cost of inaction is unacceptable.
Fig. 1 Links between ARIA and MASK for change management. CC Collaborating Center, GA2LEN Global Allergy and Asthma European network, 
GARD Global Alliance against Chronic Respiratory Diseases, MeDALL Mechanisms of the Development of ALLergy, POLLAR Impact of air POLLution 
on sleep, Asthma and Rhinitis
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POLLAR’s mission is to better understand the links 
between AR, asthma allergen exposure, sleep and pollu-
tion in order to provide preventive and treatment strate-
gies to reduce the burden of AR and asthma.
POLLAR’s ambition is to deliver an integrated solu-
tion tailored to the needs of EU citizens, employers and 
healthcare systems (including insurance companies).
POLLAR’s objective is to better manage health societal 
consequences of the disease by providing assistance dur-
ing peaks of allergens and air pollution.
POLLAR is user-designed with specific functionali-
ties adapted to patients, employers, policy makers and 
clinicians.
POLLAR’s aims are (1) to deliver a medical device/
treatment with high eligibility for the stratification of 
patients who need to be treated with OTC drugs, pre-
scribed drugs or allergen immunotherapy, (2) to pro-
vide a sentinel for air pollution and allergen exposure for 
municipalities or regions that can be relayed by media or 
social networks, (3) to help reimbursement strategies by 
health care systems or insurances, (4) to improve work 
productivity in the workplace, (5) to better understand 
the reciprocal links between AR, pollution and sleep/
sleep disorders and (6) in the end, to reduce health and 
social inequalities between and within countries.
Consortium
The consortium is led by BULL and includes EIT Health 
members from France and Spain as well as two SMEs 
(Figs. 2, 3).
  • BULL is responsible for the platform. The physician 
of the hosting platform provider (Santeos) will be 
responsible for ethical issues, privacy preservation in 
general and data mining.
  • UPMC (Université Pierre et Marie Curie, Paris, 
France) will provide the personal pollution sampler, 
medication analyses and the prediction model.
  • Grenoble University and Kyomed (France) will be in 
charge of sleep, data analysis of sleep and patients’ 
inclusion in year 2. Grenoble University will make 
innovative capabilities available for complex and big 
data analysis [60, 61].
  • ISGlobal (Global Health Institute, Barcelona, Spain) 
will be responsible for data analysis.
  • AQuAS (Agencia de Qualitat i Avaluacio Sanitaries 
de Catalunya, Barcelona, Spain) will be dedicated to 
policies.
  • Kyomed (SME, Montpellier, France) will provide 
integrated solutions (Allergy Diary) and business 
Fig. 2 The POLLAR consortium
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models, as well as support to product design, sales 
and marketing activities for the project.
  • Forum of Living Labs (Paris, France) will prepare and 
analyze the qualitative data collection of population 
awareness on air pollution and literacy.
  • The National Center of Expertise in Cognitive Stim-
ulation (CEN STIMCO, NGO, Paris, France), as a 
founding member of the Forum of Living Labs for 
Health and Independent Living (Forum LLSA, NGO, 
Paris, France), will prepare and analyze the qualita-
tive data collection of population awareness on air 
pollution and literacy.
  • Neogia (SME, Paris, France) will provide the database 
of daily trends in air pollution and allergen queries.
  • In 2019, the Alfred Health hospital will lead studies 
in Australia.
m‑Health tools and platform
POLLAR combines TRL2, TLR7 and TLR9  m-health 
tools (Fig. 3).
Allergy Diary
The existing Allergy Diary App (Android and iOS) has 
been tested in 23 countries and 17 languages. The tool 
has now been deployed to 22 Reference Sites of the Euro-
pean Innovation Partnership on Active and Healthy Age-
ing (Transfer of Innovation).
Sleep is an important component of the social conse-
quences of AR. The Allergy Diary has shown that sleep 
is impaired by some of the components of AR [22, 53]. 
A new sleep questionnaire is being added to the Allergy 
Diary (Fig. 4).
Monitoring of pollen exposure and air pollution
Monitoring of the allergy season will be carried out 
with an improved Google Trends (GT) method. How-
ever, GT has some defects [36, 37], in particular, the 
lack of quantitative data and the non-exhaustivity of 
internet. We have developed a new tool derived from 
GT (TLR2) that will analyze all trends and that will 
be quantitative for allergen and pollution. A similar 
method will be used for the assessment of air pollution 
levels.
Set up of the platform, secure storage database and tools 
for machine and deep learning
The analytic technologies have shown their limits in 
delivering accurate results and insights. The introduction 
of artificial intelligence and cognitive computing is bridg-
ing the gap. Artificial intelligence and cognitive comput-
ing provide technologies and capabilities to solve the 
challenge of ingesting large amounts of diverse data and 
to deliver more accurate and timely results and insights.
Thus, main technological challenges focus on deliver-
ing a multi-usage and agile cognitive and integrated soft-
ware suite, leveraging artificial intelligence to enable deep 
learning capabilities and fast deployments of accurate use 
cases on multiple environments.
Fig. 3 POLLAR m‑health tools
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Canarin®
To assess the individual’s exposure to air pollution in real-
time, we will use a remote sensor named  CANARIN®. 
The  CANARIN® device is intended to provide the user 
with a cost-efficient means of determining air quality 
exposure in real-time in the different places the user is 
located. CANARIN focuses on particulate matter (PM) 
of 3 sizes (0.1  µm, 2.5  µm and 10  µm). Furthermore, it 
includes a temperature and humidity sensor as these 
parameters can affect the performance of the PM sen-
sors.  It also allows the geolocalization of the carrier. All 
the data are stored via WIFI in an ad hoc cloud. CANA-
RIN has been validated.
Ethical considerations
The Allergy Diary is a CE1 application for which an 
ethical committee is not necessary. The Terms of Use 
and Privacy Policy of the App have been reviewed and 
adapted by lawyers in each of the 23 countries in order to 
account for differences between countries.
POLLAR will need ethical approval and new regula-
tions in some of the countries (e.g. Loi Jardé in France 
[62, 63]). We are currently deploying the App to 25 Refer-
ence Sites of the EIP on AHA and we have obtained ethi-
cal approval from the Köhln-Bohn Region.
The Allergy Diary is completely anonymized except 
for the geolocation aspect that has been pseudo-
anonymized. We have now used k-anonymity [64] to fully 
anonymize geolocation [65]. We are updating the ethical 
approval for POLLAR in order to comply with the GDPR 
[66].
Test case implementation (Mo 1–12)
We shall use the data from 4 countries with 20,000 users 
during the pollen season and analyse the interactions 
between air pollution, sleep and allergens.
1. Data collection
Collection of Allergy Diary data over one year during 
the pollen season (March-July or September in areas with 
ragweed pollen) and outside the pollen season (Septem-
ber–October in areas without ragweed pollen).
2. Data analysis using the Allergy Diary
 • Interactive data analysis during the pollen season.
  • Interactive data analysis outside of the pollen sea-
son.
  • Specific analyses on sleep. We will analyze the 
trajectories of symptoms reflecting sleep qual-
ity and daytime sleepiness along with exposure 
to air pollution and allergic rhinitis. We will take 
advantage of the knowledge gained from the two 
existing cross disciplinary programmes of IDEX 
Grenoble (Life is made of Choice (https ://life.
univ-greno ble-alpes .fr/)) and of the Grenoble 
data institute (https ://data-insti tute.univ-greno 
Fig. 4 MASK questions on sleep
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ble-alpes .fr). We will use innovative visualization 
tools for these trajectories that will be included 
in the Allergy Diary.
  • Interactive maps with GIS (geographic infor-
mation system) technology: GIS is one of many 
information technologies that have transformed 
the way geographers conduct research and con-
tribute to society. GIS can be viewed as an inte-
grating technology. With GIS, it is possible to 
map, model, query and analyze large quantities 
of data all held together within a single database.
3. Impact of allergy/pollution interactions on pre-
scribed medications in France
Epidemiological studies have suggested a potential 
causal relationship between air pollution and exac-
erbations of asthma and allergies. In particular, air 
pollution exposure is associated with increased medi-
cation use and need for rescue medication for asthma 
and allergies. The potential exaggerating effects of 
the interaction between pollen and air pollution on 
asthma and allergic diseases are of serious concern. 
The collection of data from pharmacy databases for 
both prescribed and over-the-counter medications 
for asthma and allergies constitutes an appropri-
ate method for studying the impact of the interac-
tion between air pollution and pollen on asthma and 
allergy aggravation.
4. Establishment of the business plan
It is expected that POLLAR will generate substantial 
and highly valuable scientific data as well as informa-
tion correlating the biological phenomena with the 
highlighted environmental factors. It is also highly 
possible that novel technologies or platforms may be 
developed as a result of the project. Both aspects are 
not only of scientific but also of commercial value. To 
capitalize on the value generated both from the data/
information and potential novel technology, Kyomed 
will establish a business plan towards the monetiza-
tion of these assets. The business plan will include 
analyses of (1) the properties, functionalities, unique-
ness and potential of the data/information or technol-
ogy generated, (2) the market trends and needs, (3) 
the competitive landscape; the competitive advantages 
of the POLLAR offer. It will make further recom-
mendations on the commercial positioning, product 
placement, pricing and promotional activities for the 
offer. Financial forecasts and budgeting will also be 
provided.
5. Education (CEN STIMCO)
Citizens and patients participating in the programme 
will gain awareness regarding the risk associated with 
air pollution. This effect will be estimated and results 
will help disseminate key messages together with the 
application.
Test case validation (Mo 12–24)
In year 2, we shall validate the results of year 1 in all EU 
countries where pollution data are available. We will also 
provide policies. The test-case implementation will be 
deployed to account for different climates (allergen expo-
sure) and pollution (low and high levels and different pol-
lutants). We shall use the existing EIP on AHA transfer of 
innovation network (25 Reference Sites across Europe in 
16 languages).
Moreover,  Canarin®, a personal pollution sampler, will 
be tested in AR patients with multimorbid sleep disor-
ders (1) to confirm the data obtained using the Allergy 
Diary and (2) to check the effect of air pollution on sleep 
and sleep apnea severity [67]. It is well documented that 
nasal obstruction associated with AR is increasing phar-
yngeal collapsibility and modulating the severity of mod-
erate to severe sleep apnea. This has been suggested by 
single night sleep studies and small intervention trails. 
However, the dynamic of the night after night evolution 
of OSA severity in relationship with air pollution and 
AR is poorly documented by repeated objective meas-
urements. The test case validation will address this issue 
by combining simplified diagnosis methods for assess-
ing the night after night evolution of OSA severity and a 
synchronization with the Allergy Diary and the Canarin 
personal pollution sampler. The impact will be huge for 
patients and the society as some OSA phenotypes might 
benefit from a better AR management and improve sleep 
apnea conditions.
Impact of POLLAR
The innovative aspect of POLLAR lies in the integra-
tion of existing hardware and software blocks (BULL) 
with newly-developed methods in a patient-centric 
designed set of easy-learning functionalities (Kyomed, 
CEN STIMCO). These will be embedded in a solution for 
all stakeholders including patients, clinicians and policy 
makers. The Allergy Diary represents an innovation that 
is creating a new market and value network and that will 
eventually disrupt the existing market and value network.
Reduction of social and health inequalities
By integrating risk perception analysis and increasing 
stakeholder engagement, POLLAR aims at (1) bringing 
more attention to the links between AR and air pollution, 
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(2) educating the public about the threat of air pollution, 
and (3) efficiently using financial resources to implement 
a more sustainable solution. POLLAR should reduce 
health and social inequalities within and between coun-
tries, in particular in vulnerable populations (children 
and old age people).
Gender dimension
Gender is an important aspect of allergic diseases. 
Before puberty, there is a male predominance of allergy 
whereas, after puberty, there is a female predominance 
[68]. Women may be more susceptible to the effects of 
air pollution. A specific gender analysis will be carried 
out in POLLAR to account for gender differences and, if 
needed, policies will be proposed.
Economic impact
The Allergy Diary can accurately measure loss of work 
productivity. It is expected that POLLAR will reduce 
these indirect costs. For industries, the demonstration 
of the link between AR incidence/severity and produc-
tivity underpins the importance of prevention, timely 
diagnosis, adequate treatment and patient compliance. 
For public healthcare organizations and private health 
insurance companies, prevention, timely diagnosis and 
effective treatments are primordial to healthcare cost 
management.
Interactions with EIT Health
EIT Health resources needed for POLLAR
EIT Health fosters cross-disciplinal collaborations to 
tackle major healthcare challenges, such as the growing 
allergy epidemic and air pollution effects. It provides a 
privileged frame for validating a comprehensive solu-
tion by paving the roads between all stakeholders. It 
also provides an integrated use of knowledge in medi-
cal device development, data management and analyt-
ics, and clinical conditions. EIT Health will interconnect 
POLLAR with its innovation project portfolio and with 
its CAMPUS (link to “Patient-centred and personal-
ized healthcare description and main outcomes”) and 
ACCELERATOR programmes, thereby catalyzing both.
Relevance of POLLAR for the core mission of EIT Health
The proposed POLLAR solution is aligned with EIT 
Health core missions: (1) Promote healthy living, lifestyle 
intervention and self-management of health, (2) Improve 
healthcare systems, treat and manage chronic diseases 
and (3) Improve work productivity.
Knowledge triangle integration
POLLAR follows the KIC knowledge triangle closely 
(Fig. 5).
Fig. 5 The POLLAR knowledge triangle
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  • Business and entrepreneurship POLLAR is typically 
designing, launching and running a new business, 
which began as a small business, such as a startup 
company (Kyomed, Neogia). It is offering a validated 
product (Allergy Diary, TLR9) which will be embed-
ded with other tools (TLR2) and scaled up. The prev-
alence of AR and asthma, and the levels of pollution 
in Europe, represent a huge business opportunity. 
Being part of the EIP on AHA, goals are an accelera-
tion of time-to-market.
  • Link to accelerator BULL is a major company which 
will help to develop new and startup companies 
(Kyomed, Neogia). It will use the business accelerator 
effect of the Forum LLSA and will provide services 
as a catalyst tool for regional and national economic 
development. It will help to scale the business of sev-
eral inter-related projects and to catapult promising 
ideas already working and tested (Allergy Diary) onto 
the market. This will support Europe’s premier inno-
vations that tackle today’s healthcare challenges (air 
pollution and allergy).
  • Research and technology The MASK pilot study has 
shown that guidelines in AR should be revised to 
account for patients’ self-management which was 
found to be unexpectedly high [21, 22, 24, 53]. The 
pilot study suggested several novel pathways for 
AR treatment. The inclusion of air pollution data is 
needed to alert patients (Allegy Diary, media, social 
networks) and to provide new recommendations for 
a better AR control [45, 69].
 • The patient’s centric approach is essential and will 
be brought by the CEN STIMCO.
  • A personalized approach targeted to each patient 
is needed and the Allergy Diary can be of great 
help [70, 71].
  • Sleep is an important component of AR and 
asthma. It should be better understood and 
embedded into guidelines.
  • The societal approach is a research project that 
will bring a novel approach to this complex disease 
allowing a holistic approach.
  • POLLAR will allow machine learning but also 
deep learning. The analytical expertise raised in 
MeDALL (Mechanisms of the Development of 
ALLergy, a success story of FP7 devoted to sys-
tems biology in allergy [57, 72]), with the tech-
nologic capabilities of BULL, will make a success 
story out of POLLAR.
  • Higher education Higher education will be provided 
by major teaching groups of Europe (UPMC, Greno-
ble University and ISGlobal) but also by the Forum 
LLA and CEN STIMCO. Some modern approaches 
will be combined with classical education. Inte-
grated training modules are needed. Because of the 
expected trends in AR, it is of paramount importance 
to train physicians, other health care professionals, 
health scientists, lawyers and socio-economic profes-
sionals. Transversal training is needed.
  • Health, chronic diseases and society POLLAR will 
combine teaching and will cover the relationship 
between chronic illnesses, chronicity, health and 
health education, ethics and the assistance relation-
ship, chronicity policies, life with a chronic illness 
and research methods in the field of human or soft 
science [73].
  • Management education The overall care of people 
suffering from chronic illness requires the coordi-
nation of people who will help them throughout 
life. The case manager is a unique correspondent in 
charge of coordinating care.
  • Patient therapeutic education will also be provided in 
collaboration with patients’ organizations (involved 
in the Allergy Diary).
Benefits for the citizens and the patients
Guidelines have improved the knowledge on rhinitis and 
made a significant impact on AR management. How-
ever, many patients are insufficiently controlled and the 
costs for society are enormous. Allergic Rhinitis and its 
Impact on Asthma (ARIA) has evolved from a guideline 
to care pathways using mobile technology in AR and 
asthma multimorbidity. ARIA appears to be close to the 
patient’s needs but real-life data obtained using an App 
in 22 countries have shown that very few patients use 
guidelines and that they often self-medicate. Moreo-
ver, patients largely use OTC medications dispensed in 
pharmacies. Self-medication and shared decision mak-
ing (SDM) centered around the patient should be used 
more often. The knowledge by patients of peaks of air 
pollution and allergens will help them to better control 
their disease. In POLLAR, self-medication strategies and 
a sentinel network will be integrated in care pathways to 
optimize the treatment of AR and asthma multimorbid-
ity. These changes should prepare and support individu-
als, teams and organizations in making organizational 
change centered around the patient.
Political agenda
POLLAR is supported by several national and interna-
tional scientific societies (including EAACI, ERS, IPCRG) 
and patients’ organizations (EFA and ELF).
One of the POLLAR members is AQuaS (Agencia de 
Qualitat i Avaluacio Sanitaries de Catalunya, Barcelona, 
Spain).
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The EIP on AHA is involved in POLLAR through the 
Reference Site Collaborative Network (J Bousquet, M 
Illario).
POLLAR is a WHO GARD (Global Alliance against 
Chronic Respiratory Diseases) demonstration project.
Conclusion
POLLAR aims to propose novel care pathways integrat-
ing pollution, sleep and patients’ literacy. It also aims to 
study the sleep consequences of pollution and its impact 
on frequent chronic diseases, to improve work produc-
tivity, to propose the basis for a sentinel network at the 
EU level for pollution and allergy, and to assess the soci-
etal implications of the interaction.
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